Parainfluenza Virus Type 3 Overview

Save information for later
Sign Up

Learn About Parainfluenza Virus Type 3

What is the definition of Parainfluenza Virus Type 3?
Parainfluenza virus type 3 is one of a group of common viruses known as human parainfluenza viruses (HPIV) that cause a variety of respiratory illnesses. Symptoms usually develop between 2 and 7 days from the time of exposure and typically resolve in 7-10 days. Symptoms may include fever, runny nose, and cough. HPIV-3 can also cause bronchiolitis, bronchitis, and pneumonia. Infants and young children are particularly susceptible to HPIV-3 infections, though older adults and those with a weakened immune system are also at risk for complications. HPIVs are usually spread from an infected person to others through coughing, sneezing, and/or touching. Most adults have antibodies against parainfluenza but can get repeat infections.
What are the alternative names for Parainfluenza Virus Type 3?
  • Parainfluenza virus type 3
  • Human parainfluenza virus type 3
  • PIV3
Who are the top Parainfluenza Virus Type 3 Local Doctors?
Experienced in Parainfluenza Virus Type 3
Dr. Michael D. Gruber
Family Medicine
Experienced in Parainfluenza Virus Type 3
Dr. Michael D. Gruber
Family Medicine
106 Blanca Ave Ste 300, 
Alamosa, CO 
 (36.3 mi)
719-589-3658
Languages Spoken:
English

Michael Gruber is a Family Medicine provider in Alamosa, Colorado. Dr. Gruber and is rated as an Experienced provider by MediFind in the treatment of Parainfluenza Virus Type 3. His top areas of expertise are Mucormycosis, Bronchitis, Allergic Rhinitis, and Sinusitis.

Experienced in Parainfluenza Virus Type 3
Dr. Mugabe N. Walker
Internal Medicine
Experienced in Parainfluenza Virus Type 3
Dr. Mugabe N. Walker
Internal Medicine

Lutheran Hospital Association Of The San Luis Valley

2115 Stuart Ave, 
Alamosa, CO 
 (37.6 mi)
719-589-3000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mugabe Walker is an Internal Medicine provider in Alamosa, Colorado. Dr. Walker and is rated as an Experienced provider by MediFind in the treatment of Parainfluenza Virus Type 3. His top areas of expertise are Cerebral Hypoxia, Maturity Onset Diabetes of the Young, Hypothyroidism, and Type 2 Diabetes (T2D).

 
 
 
 
Learn about our expert tiers
Learn More
Experienced in Parainfluenza Virus Type 3
Dr. Greta M. Ivers
Family Medicine
Experienced in Parainfluenza Virus Type 3
Dr. Greta M. Ivers
Family Medicine

Valley Citizens' Foundation For Health Care Inc

1033 2nd Ave, 
Monte Vista, CO 
 (37.7 mi)
719-852-8827
Languages Spoken:
English
See accepted insurances

Greta Ivers is a Family Medicine provider in Monte Vista, Colorado. Dr. Ivers and is rated as an Experienced provider by MediFind in the treatment of Parainfluenza Virus Type 3. Her top areas of expertise are Shingles, Hartsfield Syndrome, Gout, and Glucocorticoid-Remediable Aldosteronism.

View All Doctors
What are the latest Parainfluenza Virus Type 3 Clinical Trials?
A Phase 1, Dose-Escalation, Randomized, Active-Controlled, Modified Double-Blind, Parallel-Group, Multi-Arm Study to Investigate the Safety and Immunogenicity of a Combined Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adult Participants Aged 60 Years and Older
A Phase 1, Dose-Escalation, Randomized, Active-Controlled, Modified Double-Blind, Parallel-Group, Multi-Arm Study to Investigate the Safety and Immunogenicity of a Combined Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adult Participants Aged 60 Years and Older
Enrollment Status: Recruiting
Publish Date: October 26, 2024
Intervention Type: Biological
Study Phase: Phase 1

Summary: The purpose of this phase 1 study is to evaluate whether the vaccine is safe and can help the body to develop germ fighting agents called antibodies (immunogenicity) against the respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and parainfluenza virus type 3 (PIV3). The study will use different doses of PIV3 only and different combinations of RSV/hMPV/PIV3 or RSV/hMPV or only RSV va...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase I Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, Bovine/Human, Parainfluenza Virus Type 3 (B/HPIV3) Vectored Vaccines Expressing the Fusion Glycoprotein of Human Metapneumovirus (HMPV), Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age
Phase I Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, Bovine/Human, Parainfluenza Virus Type 3 (B/HPIV3) Vectored Vaccines Expressing the Fusion Glycoprotein of Human Metapneumovirus (HMPV), Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age
Enrollment Status: Recruiting
Publish Date: August 12, 2024
Intervention Type: Drug, Biological
Study Phase: Phase 1

Summary: HPIV3 and HMPV are viruses that can cause breathing problems in children. The goal of this clinical trial is to look at the safety of 2 experimental HPIV3/HMPV vaccines in HPIV3-seropositive children ≥ 24 months to \< 60 months of age. Children will receive B/HPIV3/HMPV-PreF-A vaccine, B/HPIV3/HMPV-F-B365 vaccine, or placebo, and participants will not know which study product they have received. T...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center